395 related articles for article (PubMed ID: 32663379)
1. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study.
Vadhan-Raj S; McNamara MG; Venerito M; Riess H; O'Reilly EM; Overman MJ; Zhou X; Vijapurkar U; Kaul S; Wildgoose P; Khorana AA
Cancer Med; 2020 Sep; 9(17):6196-6204. PubMed ID: 32663379
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
Khorana AA; Soff GA; Kakkar AK; Vadhan-Raj S; Riess H; Wun T; Streiff MB; Garcia DA; Liebman HA; Belani CP; O'Reilly EM; Patel JN; Yimer HA; Wildgoose P; Burton P; Vijapurkar U; Kaul S; Eikelboom J; McBane R; Bauer KA; Kuderer NM; Lyman GH;
N Engl J Med; 2019 Feb; 380(8):720-728. PubMed ID: 30786186
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
[TBL] [Abstract][Full Text] [Related]
5. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
Samama CM; Laporte S; Rosencher N; Girard P; Llau J; Mouret P; Fisher W; Martínez-Martín J; Duverger D; Deygas B; Presles E; Cucherat M; Mismetti P;
N Engl J Med; 2020 May; 382(20):1916-1925. PubMed ID: 32223113
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Suh E; Spiro TE; Barnathan ES; Raskob GE;
N Engl J Med; 2018 Sep; 379(12):1118-1127. PubMed ID: 30145946
[TBL] [Abstract][Full Text] [Related]
8. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer.
Wang Y; Wang M; Ni Y; Liang Z
Hematology; 2020 Dec; 25(1):63-70. PubMed ID: 31984870
[No Abstract] [Full Text] [Related]
9. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
10. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
12. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.
Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos A; Tapson V
J Thromb Thrombolysis; 2011 May; 31(4):407-16. PubMed ID: 21359646
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of rivaroxaban for the prevention of thrombosis following total hip or knee replacement: A systematic review and meta-analysis.
Liu J; Zhao J; Yan Y; Su J
Medicine (Baltimore); 2019 Mar; 98(9):e14539. PubMed ID: 30817570
[TBL] [Abstract][Full Text] [Related]
14. Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial.
Khorana AA; McNamara MG; Kakkar AK; Streiff MB; Riess H; Vijapurkar U; Kaul S; Wildgoose P; Soff GA;
TH Open; 2020 Apr; 4(2):e107-e112. PubMed ID: 32462111
[No Abstract] [Full Text] [Related]
15. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
16. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.
Khorana AA; Francis CW; Kuderer NM; Carrier M; Ortel TL; Wun T; Rubens D; Hobbs S; Iyer R; Peterson D; Baran A; Kaproth-Joslin K; Lyman GH
Thromb Res; 2017 Mar; 151():89-95. PubMed ID: 28139259
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Rivaroxaban for Postoperative Thromboprophylaxis in Patients After Bariatric Surgery: A Randomized Clinical Trial.
Kröll D; Nett PC; Rommers N; Borbély Y; Deichsel F; Nocito A; Zehetner J; Kessler U; Fringeli Y; Alberio L; Candinas D; Stirnimann G
JAMA Netw Open; 2023 May; 6(5):e2315241. PubMed ID: 37227726
[TBL] [Abstract][Full Text] [Related]
18. Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results.
Wells PS; Lensing AWA; Haskell L; Levitan B; Laliberté F; Durkin M; Ashton V; Xiao Y; Crivera C; Lejeune D; Schein J; Lefebvre P
J Med Econ; 2018 Jun; 21(6):587-594. PubMed ID: 29469638
[TBL] [Abstract][Full Text] [Related]
19. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial.
Ageno W; Bertù L; Bucherini E; Camporese G; Dentali F; Iotti M; Lessiani G; Parisi R; Prandoni P; Sartori M; Visonà A; Bigagli E; Palareti G;
BMJ; 2022 Nov; 379():e072623. PubMed ID: 36520715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]